

Systemic Anti Cancer Treatment Protocol

Vinorelbine Advanced Breast Cancer

**PROTOCOL REF: MPHAVINOBR
(Version No: 1.1)**

The protocol has been temporarily amended – please see the Oral SACT Operational Changes during Covid-19. Amendments may include less frequent blood monitoring, telephone SACT assessments and longer durations of treatment being dispensed.

Approved for use:

As an option for second or subsequent line treatment for locally advanced/ metastatic breast cancer

Dosage:

Oral regimen

| Drug | Dosage | Route | Frequency |
|-------------|--|-------|--|
| Vinorelbine | 60mg/m ² Can be increased to 80mg/m ² from the 3 rd administration onwards if tolerated* Maximum dose 160mg weekly | Oral | Days 1 and 8 of 21 day cycle Until disease progression or unacceptable toxicity |

If unsuitable for dose escalation to 80mg/m² consider increasing frequency to include day 15 if treatment tolerated well and patient has good performance status.

Consider using the oral route first line. In case of swallowing difficulties or persistent nausea and vomiting, switch to the IV route.

| Oral dose | Equivalent IV dose |
|---------------------|---------------------|
| 80mg/m ² | 30mg/m ² |
| 60mg/m ² | 25mg/m ² |

Intravenous regimen

| Drug | Dosage | Route | Frequency |
|-------------|---|-------|--|
| Vinorelbine | 25mg/m ² Can be increased to 30mg/m ² from the 3 rd administration onwards if tolerated*. | IV | Days 1 and 8 of 21 day cycle Until disease progression or unacceptable toxicity |

*Dose Escalation

| ANC during the first 3 administrations of 60 mg/m ² /week | ANC > 1.0 x 10 ⁹ /L | 0.5 ≤ ANC < 1.0 x 10 ⁹ /L 1 episode | 0.5 ≤ ANC < 1.0 x 10 ⁹ /L 2 episodes | ANC < 0.5 x 10 ⁹ /L |
|---|--------------------------------|---|--|--------------------------------|
| Recommended oral dose starting with the 4th administration (mg/m ²) | 80 mg/m ² | 80 mg/m ² | 60 mg/m ² | 60 mg/m ² |

Dose Modification

| ANC beyond the 4th administration of 80 mg/m ² /week | ANC > 1.0 x 10 ⁹ /L | 0.5 ≤ ANC < 1.0 x 10 ⁹ /L 1 episode | 0.5 ≤ ANC < 1.0 x 10 ⁹ /L 2 episodes | ANC < 0.5 x 10 ⁹ /L |
|--|--------------------------------|---|--|--------------------------------|
| Recommended oral dose starting with the next administration (mg/m ²) | 80 mg/m ² | | 60 mg/m ² | |

Supportive treatments:

Dexamethasone 4mg orally twice daily for 3 days for oral vinorelbine

Domperidone 10mg tablets orally three times a day as required

Extravasation risk:

Vinorelbine (IV): vesicant

Refer to the network guidance for the prevention and management of extravasation.

Drug Interactions

Concomitant use with live attenuated vaccines, phenytoin and itraconazole is not recommended; please refer to the SmPC for full details on the nature of the interaction.

Vinca-alkaloids are known as substrates for P-glycoprotein, and in the absence of specific study, caution should be exercised when combining vinorelbine with strong modulators (cyclosporine, digoxin, diltiazem, verapamil, simvastatin etc.) of this membrane transporter.

Caution is strongly recommended when vinorelbine is used in combination with strong inducers (rifampicin, carbamazepine, phenobarbital, phenytoin etc.) or inhibitors (clarithromycin, fluconazole, erythromycin, nefazodone, itraconazole, ketoconazole, HIV protease inhibitors etc.) of the CYP 3A4 isoenzyme.

Administration:

Oral regimen

| Day | Drug | Dose | Route | Diluent and rate |
|-----|--------------------|--|-------------|---------------------------------|
| 1 | Ondansetron | 16mg | Oral | 30 minutes prior to vinorelbine |
| | Dexamethasone | 8mg | Oral | 30 minutes prior to vinorelbine |
| | Vinorelbine | 60 mg/m² or 80mg/m² | Oral | |
| 8 | Ondansetron | 16mg | Oral | 30 minutes prior to vinorelbine |
| | Dexamethasone | 8mg | Oral | 30 minutes prior to vinorelbine |
| | Vinorelbine | 60mg/m² or 80mg/m² | Oral | |

- Due to sorbitol content, patients with rare hereditary problems with fructose intolerance should not take the capsules.

- The liquid content within the capsules is irritant and therefore contact with skin, mucosa or eyes should be strictly avoided. If accidental contact occurs the affected area should be rinsed immediately with water or preferably normal saline solution. Damaged/broken capsules should not be swallowed and instead disposed of appropriately and pharmacy informed.
- The capsules should be swallowed whole with water, not chewing or sucked. If this occurs, rinse mouth out with water or preferably a normal saline solution.
- In the case of vomiting within a few hours after drug intake, do not re-administer.
- Vinorelbine soft capsule is associated with a higher incidence of nausea/vomiting than the intravenous formulation. Primary prophylaxis with anti-emetics and administration of the capsules with some food is recommended as this has also been shown to reduce the incidence of nausea and vomiting.
- Patients receiving concomitant morphine or opioid analgesics: laxatives and careful monitoring of bowel mobility are recommended. Prescription of laxatives may be appropriate in patients with prior history of constipation.

Intravenous regimen

| Day | Drug | Dose | Route | Diluent and rate |
|-----|-------------|---|-------|--|
| 1 | Vinorelbine | 25 mg/m ² or 30mg/m ² | IV | 50mL Sodium Chloride 0.9% over 10 minutes |
| 8 | Vinorelbine | 25mg/m ² or 30mg/m ² | IV | 50mL Sodium Chloride 0.9% over 10 minutes |

Administration should always be followed by a 250ml sodium chloride 0.9% infusion to flush the vein.

Main Toxicities:

| | |
|---|--|
| Haematological | Neutropenia, anaemia, thrombocytopenia, |
| Gastrointestinal | Nausea, vomiting, diarrhoea, constipation, mucositis |
| Nervous system | Peripheral neuropathy |
| Hepatobiliary | Elevation of liver transaminases, alkaline phosphatase and bilirubin. |
| Skin and subcutaneous tissue disorders | Alopecia Allergic reaction |
| General disorders and administration site conditions | Fatigue, insomnia, visual disorders, dyspnoea Infertility, early menopause With intravenous preparation care during administration is crucial as extravasation can lead to significant skin damage |

Investigations:

| | Pre | C1 | C1D8 | C2D1 | C2D8 dose increase recommended | Ongoing |
|-----------------------|-----|----|------|------|--------------------------------------|--|
| Medical Assessment | X | | | X | X | Every cycle |
| Nursing Assessment | | X | X | X | X | Every treatment |
| FBC | X | | X | X | X | Every treatment |
| U&E & LFT | X | | X | X | X | Every treatment |
| Informed Consent | X | | | | | |
| CT scan | X | | | | | Every 8 to 12 weeks as clinically indicated |
| PS recorded | X | X | X | X | X | Every treatment |
| Toxicities documented | X | | X | X | X | Every treatment |
| Weight recorded | X | X | X | X | X | Every treatment |

Dose Modifications:**Haematological Toxicity:**

Proceed on day 1 if-

| | |
|--|--|
| $\text{Plt} \geq 100 \times 10^9/\text{L}$ | $\text{ANC} \geq 1.0 \times 10^9/\text{L}$ |
|--|--|

Delay 1 week on day 1 if-

| | |
|---|--|
| $\text{Plt} \leq 99 \times 10^9/\text{L}$ | $\text{ANC} \leq 0.9 \times 10^9/\text{L}$ |
|---|--|

Proceed on day 8 if-

| | |
|---|--|
| $\text{Plt} \geq 75 \times 10^9/\text{L}$ | $\text{ANC} \geq 1.0 \times 10^9/\text{L}$ |
|---|--|

Omit on day 8 if-

| | |
|---|--|
| $\text{Plt} \leq 74 \times 10^9/\text{L}$ | $\text{ANC} \leq 0.9 \times 10^9/\text{L}$ |
|---|--|

On day 8 of the cycle if blood results do not meet the above levels the patient will miss that dose and proceed to the next cycle.

These haematological guidelines assume that patients are well with good performance status, that other acute toxicities have resolved and the patient has not had a previous episode of neutropenic sepsis.

Non-haematological Toxicity**Renal Impairment:**

No dose adjustment is necessary.

Hepatic Impairment

AST/ALT > 5 x ULN or bilirubin > 2 x ULN- reduce dose by a third.

In breast cancer patients, clearance is not altered in presence of moderate liver metastases (i.e. <75% of liver volume replaced by the tumour). In these patients there is no pharmacokinetic rationale for reducing doses. In patients with massive liver metastases (i.e. >75% of liver volume replaced by the tumour), it is suggested that the dose is reduced by 1/3 and the haematological toxicity closely followed.

References:

NICE guideline 'Advanced Breast Cancer: Diagnosis and Treatment' (CG81) - accessed 14th of June 2018.

SmPC Navelbine 20mg soft capsule and 10mg/mL concentrate for infusion - accessed 19th June 2018

The North London Cancer Network (2009) 'Dosage Adjustment for Cytotoxics in Hepatic Impairment'.

| | | |
|---|---|--------------------------------|
| Issue Date: 6 th May 2020 Review Date: May 2023 | Page 7 of 7 | Protocol reference: MPHAVINOBR |
| Author: Helen Flint | Authorised by: Helen Poulter-Clark & Joanne McCaughey | Version No: 1.1 |